Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT05111015
Recruiting Observational

Tracking Results of Ablations to Combat AF Registry Generation 2

NCT05111015 · tracked via the Priya Life Science Canada tracker
Sponsor
AtriCure, Inc
Phase
Observational
Started
2024-03-11
Last updated
2026-06-29

Condition(s) studied

Atrial Fibrillation

Investigational drug(s) / intervention(s)

Open Concomitant Surgical Ablation ProceduresHybrid (Convergent) Ablation ProceduresAtriCure Hybrid Totally Thoracoscopic Ablation ProceduresAtriCure LAA Exclusion Procedures

Open Concomitant Surgical Ablation Procedures: AtriCure's Open Concomitant Surgical Ablation Devices used for the management of Atrial Fibrillation.

Hybrid (Convergent) Ablation Procedures: AtriCure's Hybrid (Convergent) Ablation Devices used for the management of Atrial Fibrillation.

AtriCure Hybrid Totally Thoracoscopic Ablation Procedures: AtriCure's Hybrid Totally Thoracoscopic Surgical Ablation Devices used for the management of Atrial Fibrillation.

AtriCure LAA Exclusion Procedures: AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the management of Atrial Fibrillation.

Study summary

The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patient has been scheduled by physician(s) to undergo or has undergone cardiac ablation procedure(s) 2. Patient is willing to provide informed consent 3. Patient whose age is 18 years or above, or of legal age to give informed consent specific to state and national law Exclusion Criteria: 1\. Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the subject from appropriate consent or adherence to the protocol.

Primary outcome measure(s)

Trial sites (29)

FacilityCityRegionStatus
Huntsville Hospital Huntsville Alabama Recruiting
St. Bernards Medical Center Jonesboro Arkansas Recruiting
CHI St. Vincent Heart Institute Little Rock Arkansas Recruiting
Loma Linda University Medical Center Loma Linda California Recruiting
Adventist Heart Institute (St. Helena Hospital) St. Helena California Recruiting
Valley View Hospital Glenwood Springs Colorado Recruiting
MedStar Washington Hospital Washington D.C. District of Columbia Recruiting
Delray Medical Center Delray Beach Florida Recruiting
University of Florida Gainesville Florida Recruiting
Orlando Health Heart & Vascular Institute Orlando Florida Recruiting
St. Joseph's Hospital (BayCare) Tampa Florida Recruiting
Franciscan Health Indianapolis Indiana Recruiting
Kansas City Heart Rhythm Institute Overland Park Kansas Recruiting
Norton Heart & Vascular Institute Louisville Kentucky Recruiting
University of Michigan Ann Arbor Michigan Recruiting
Corewell Health Grand Rapids Michigan Recruiting
Washington University School of Medicine St Louis Missouri Recruiting
University of Nebraska Medical Center Omaha Nebraska Recruiting
Maimonides Health Heart & Vascular Institute Brooklyn New York Recruiting
Vassar Brothers Medical Center Poughkeepsie New York Recruiting
Atrium Health Wake Forest Baptist Winston-Salem North Carolina Recruiting
UH Cleveland Harrington Heart & Vascular Institute Cleveland Ohio Recruiting
Jackson Madison County General Hospital Jackson Tennessee Recruiting
Centennial Medical Center Nashville Tennessee Recruiting
Michael E. DeBakey VAMC - Houston Houston Texas Recruiting
Medical College of Wisconsin Milwaukee Wisconsin Recruiting
Medical University of Vienna Vienna Austria Recruiting
Nova Scotia Health Authority Halifax Nova Scotia Recruiting
Waterloo Regional Health Network Kitchener Ontario Recruiting

More AtriCure, Inc. trials in Canada

BoxX-NoAF Clinical Trial Recruiting
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial Active, not recruiting

Other trials for the same condition

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation Recruiting
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG Recruiting
Surgical Ablation of AF Efficacy Trial Recruiting
A Behavioural Weight Loss Intervention Delivered in Cardiac Rehabilitation for Patients With Atrial Fibrillation and Obesity Active, not recruiting
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05111015 on ClinicalTrials.gov ↗ ← All trials in Canada